Literature DB >> 1654453

Increased expression in vivo and in vitro of foreign genes directed by A-type inclusion body hybrid promoters in recombinant vaccinia viruses.

S Funahashi1, S Itamura, H Iinuma, K Nerome, M Sugimoto, H Shida.   

Abstract

We constructed A-type inclusion body (ATI) hybrid promoters, that is, late ATI promoters followed by tandemly repeated early regions of the promoter for the 7.5-kDa protein (the 7.5-kDa promoter). The repetition of the whole early promoter sequence of the 7.5-kDa gene, including the upstream consensus sequence and initiation region, efficiently increased the early expression of the bacterial chloramphenicol acetyltransferase gene in recombinant vaccinia virus. Recombinant vaccinia virus could express influenza virus hemagglutinin via the hybrid promoter more efficiently, induced higher levels of neutralizing antibody and cytotoxic T lymphocytes, and consequently protected mice more efficiently against challenge with influenza virus than did recombinant vaccinia virus containing the widely used 7.5-kDa promoter.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654453      PMCID: PMC249070     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus.

Authors:  S Funahashi; T Sato; H Shida
Journal:  J Gen Virol       Date:  1988-01       Impact factor: 3.891

Review 2.  Vaccinia virus expression vectors.

Authors:  B Moss; C Flexner
Journal:  Annu Rev Immunol       Date:  1987       Impact factor: 28.527

Review 3.  Vaccinia: virus, vector, vaccine.

Authors:  A Piccini; E Paoletti
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

4.  Structure of vaccinia virus late promoters.

Authors:  A J Davison; B Moss
Journal:  J Mol Biol       Date:  1989-12-20       Impact factor: 5.469

5.  Structure of vaccinia virus early promoters.

Authors:  A J Davison; B Moss
Journal:  J Mol Biol       Date:  1989-12-20       Impact factor: 5.469

6.  Development of heat-stable recombinant rinderpest vaccine.

Authors:  K Tsukiyama; Y Yoshikawa; H Kamata; K Imaoka; K Asano; S Funahashi; T Maruyama; H Shida; M Sugimoto; K Yamanouchi
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  Improved oligonucleotide site-directed mutagenesis using M13 vectors.

Authors:  P Carter; H Bedouelle; G Winter
Journal:  Nucleic Acids Res       Date:  1985-06-25       Impact factor: 16.971

8.  Nucleotide sequence of the vaccinia virus hemagglutinin gene.

Authors:  H Shida
Journal:  Virology       Date:  1986-04-30       Impact factor: 3.616

9.  Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection.

Authors:  H Shida; T Tochikura; T Sato; T Konno; K Hirayoshi; M Seki; Y Ito; M Hatanaka; Y Hinuma; M Sugimoto
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

10.  Messenger RNAs of a strongly-expressed late gene of cowpox virus contain 5'-terminal poly(A) sequences.

Authors:  D D Patel; D J Pickup
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  7 in total

1.  Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses.

Authors:  Karen Baur; Kay Brinkmann; Marc Schweneker; Juliane Pätzold; Christine Meisinger-Henschel; Judith Hermann; Robin Steigerwald; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Fusion formation by the uncleaved spike protein of murine coronavirus JHMV variant cl-2.

Authors:  F Taguchi
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

3.  Constructions of vaccinia virus A-type inclusion body protein, tandemly repeated mutant 7.5 kDa protein, and hemagglutinin gene promoters support high levels of expression.

Authors:  N Y Jin; S Funahashi; H Shida
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

4.  Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein.

Authors:  H Kubo; Y K Yamada; F Taguchi
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

5.  A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses.

Authors:  Sonia T Wennier; Kay Brinkmann; Charlotte Steinhäußer; Nicole Mayländer; Claudia Mnich; Ursula Wielert; Ulrike Dirmeier; Jürgen Hausmann; Paul Chaplin; Robin Steigerwald
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

6.  A Robust System for Production of Superabundant VP1 Recombinant AAV Vectors.

Authors:  Qizhao Wang; Zhongren Wu; Junping Zhang; Jenni Firrman; Hongying Wei; Zhengjing Zhuang; LinShu Liu; Linqing Miao; Yang Hu; Dong Li; Yong Diao; Weidong Xiao
Journal:  Mol Ther Methods Clin Dev       Date:  2017-11-07       Impact factor: 6.698

7.  SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus.

Authors:  Masahiro Kitabatake; Shingo Inoue; Fumihiko Yasui; Shoji Yokochi; Masaaki Arai; Kouichi Morita; Hisatoshi Shida; Minoru Kidokoro; Fukashi Murai; Mai Quynh Le; Kyosuke Mizuno; Kouji Matsushima; Michinori Kohara
Journal:  Vaccine       Date:  2006-09-11       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.